Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

20181,030 citationsJournal Articlegreen Open Access

Authors

Maha Hussain · Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Karim Fizazi · Université Paris-Sud

Fred Saad · Université de Montréal

Per Rathenborg · Herlev Hospital

Neal D. Shore · Carolina Urologic Research Center

Ubirajara Ferreira

Petro Ivashchenko · Kyiv City Clinical Oncology Center

Abstract

Among men with nonmetastatic, castration-resistant prostate cancer with a rapidly rising PSA level, enzalutamide treatment led to a clinically meaningful and significant 71% lower risk of metastasis or death than placebo. Adverse events were consistent with the established safety profile of enzalutamide. (Funded by Pfizer and Astellas Pharma; PROSPER ClinicalTrials.gov number, NCT02003924 .).

Topics & Keywords

Prostate Cancer Treatment and Research Cancer, Lipids, and Metabolism Hormonal and reproductive studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 378, Issue 26, pp. 2465-2474

DOI: 10.1056/nejmoa1800536

Field-Weighted Citation Impact: 108.55